ULGX (Urologix) Cyclically Adjusted PB Ratio: (As of Sep. 10, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Urologix Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Urologix  (OTCPK:ULGX) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Urologix Cyclically Adjusted PB Ratio Related Terms


Urologix Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Urologix's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Urologix Cyclically Adjusted PB Ratio Chart

Urologix Annual Data
Trend Jun05 Jun06 Jun07 Jun08 Jun09 Jun10 Jun11 Jun12 Jun13 Jun14
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Urologix Quarterly Data
Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

ULGX vs MFST, GTHP, ESMC: Cyclically Adjusted PB Ratio Comparison

For the Medical Devices subindustry, Urologix's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Urologix Cyclically Adjusted PB Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Urologix's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Urologix's Cyclically Adjusted PB Ratio falls into.



Urologix Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Urologix's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2015 is calculated as:

For example, Urologix's adjusted Book Value per Share data for the three months ended in Mar. 2015 was:

Adj_Book=Book Value per Share/CPI of Mar. 2015 (Change)*Current CPI (Mar. 2015)
=-0.379/236.1190*236.1190
=-0.379

Current CPI (Mar. 2015) = 236.1190.

Urologix Quarterly Data

Book Value per Share CPI Adj_Book
200506 2.317 194.500 2.813
200509 2.352 198.800 2.794
200512 2.398 196.800 2.877
200603 2.446 199.800 2.891
200606 2.790 202.900 3.247
200609 2.778 202.900 3.233
200612 2.805 201.800 3.282
200703 2.769 205.352 3.184
200706 1.945 208.352 2.204
200709 1.933 208.490 2.189
200712 1.242 210.036 1.396
200803 1.106 213.528 1.223
200806 0.966 218.815 1.042
200809 0.877 218.783 0.946
200812 0.814 210.228 0.914
200903 0.738 212.709 0.819
200906 0.689 215.693 0.754
200909 0.650 215.969 0.711
200912 0.641 215.949 0.701
201003 0.605 217.631 0.656
201006 0.568 217.965 0.615
201009 0.525 218.439 0.567
201012 0.483 219.179 0.520
201103 0.421 223.467 0.445
201106 0.334 225.722 0.349
201109 0.249 226.889 0.259
201112 0.180 225.672 0.188
201203 0.120 229.392 0.124
201206 0.043 229.478 0.044
201209 0.169 231.407 0.172
201212 0.123 229.601 0.126
201303 0.077 232.773 0.078
201306 0.020 233.504 0.020
201309 -0.041 234.149 -0.041
201312 -0.090 233.049 -0.091
201403 -0.167 236.293 -0.167
201406 -0.333 238.343 -0.330
201409 -0.351 238.031 -0.348
201412 -0.363 234.812 -0.365
201503 -0.379 236.119 -0.379

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Urologix Business Description

Address 14405 21st Avenue North, Suite 110, Minneapolis, MN, USA, 55447
Urologix Inc is a United States-based company engaged in the development, manufacturing, and marketing of minimally invasive medical products for the treatment of obstruction and symptoms due to Benign Prostatic Hyperplasia (BPH). The firm markets the Cooled ThermoTherapy (CTC) product line and the Prostiva Radio Frequency (RF) Therapy System (Prostiva). The CTC produces targeted microwave energy combined with a cooling mechanism to protect healthy tissue and enhance patient comfort. The Prostiva delivers radio frequency energy directly into the prostate destroying prostate tissue, reducing constriction of the urethra, and thereby relieving BPH voiding symptoms. The CTC product line includes the CoolWave and Targis Control Units and the CTC Advance catheter.